Showing results (751-760 of 785) with videos related to

Sort By:
Pageof 79
The American Journal of Gastroenterology|November 19, 2021
Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel DiseaseGil Y Melmed, Brant Oliver, Jason K Hou, et al.
Cell|June 7, 2025
Microbiome mismatches from microbiota transplants lead to persistent off-target metabolic and immunomodulatory effectsOrlando DeLeon, Mora Mocanu, Alan Tan, et al.
BMJ Open Gastroenterology|February 20, 2026
Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trialVipul Jairath, Sudheer K Vuyyuru, Guangyong Zou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 29, 2026
Patient-reported Outcomes in Clinical Trials of Inflammatory Bowel Disease: A Systematic Review and Meta-analysisJurij Hanzel, Yuhong Yuan, Shane W Goodwin, et al.
Clinical Pharmacology and Therapeutics|December 17, 2016
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation ProgramR P McKillip, B A Borden, P Galecki, et al.
Gastroenterology|April 19, 2026
Pre-Crohn's Disease Stool from Discordant Siblings Promotes the Development of Colitis in Germ-Free MiceCong Phi Dang, Alice Chen-Liaw, Mingyue Xue, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 28, 2025
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitisSailish Honap, Joelle St-Pierre, Michael Colwill, et al.
Inflammatory Bowel Diseases|May 6, 2022
Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International StudyGassan Kassim, Clara Yzet, Nilendra Nair, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Pageof 79